Regular colorectal cancer (CRC) screening may help
reduce mortality rates and has the potential to save lives

The U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) both recommend screening patients at average risk for CRC starting at age 45.1,2

(Grade B recommendation)1*†

Of the ~44 million average-risk patients aged 45 and older eligible for CRC screening3:
~19 Million
Screening-eligible patients are aged 45 to 49 years3

Despite the American Cancer Society (ACS) lowering its initial screening age to 45 in 20182:

Only 1 in 5 patients aged 45 to 49 years recently reported screening for CRC4
Initiating CRC screening at age 45 provides multiple benefits according to projection models, including averted CRC cases, a reduction in CRC-related deaths, and an increase in patient life-years gained.1
  • Incidence and severity in patients <50

    CRC incidence in younger populations is estimated to increase by 90% by 20305‡

    Among patients younger than 50 years:

    Increase in the incidence
    of CRC since 19942
    Were diagnosed with more
    advanced stages of CRC vs
    40% of patients aged 50+ years

There is a significant risk in waiting to screen for CRC7

Many patients with early-stage CRC
have no symptoms, making proactive
screening the only way to detect CRC8
Survival Rate
The 5-year relative survival rate
(stages I and II)|| is 90%, but when
diagnosed in stage IV, that number
drops to 15%7

5-year survival rates by stage of CRC7,9||:

Stages I, IIa, IIb (Localized)
Stages IIc, III (Regional)
Stage IV (Distant)

Unfortunately, more than half of patients are diagnosed with regional or distant disease.

Financial impact

For each patient
diagnosed in stage I or II


is the average cost of first-year
CRC treatment10#**
For each patient
diagnosed in stage IV


Is the average cost of first-year
CRC treatment10**